Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C35H30N4O4 |
Molecular Weight | 570.6371 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@H]([C@@H](OC)[C@](C)(O1)N3C4=CC=CC=C4C5=C6CNC(=O)C6=C7C8=C(C=CC=C8)N2C7=C35)N(C)C(=O)C9=CC=CC=C9
InChI
InChIKey=BMGQWWVMWDBQGC-IIFHNQTCSA-N
InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1
Molecular Formula | C35H30N4O4 |
Molecular Weight | 570.6371 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10454207Curator's Comment: description was created based on several sources, including:
https://www.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-granted-fda-priority-review-newly-diagnosed | http://adisinsight.springer.com/drugs/800002524
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10454207
Curator's Comment: description was created based on several sources, including:
https://www.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-granted-fda-priority-review-newly-diagnosed | http://adisinsight.springer.com/drugs/800002524
Midostaurin, a derivate of staurosporine (N-benzoylstaurosporine), is a broad-spectrum inhibitor of Ser/Thr and Tyr protein kinases. Midostaurin showed broad antiproliferative activity against various tumor and normal cell lines in vitro and is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. Midostaurin showed in vivo antitumor activity as single agent and inhibited angiogenesis in vivo. At the end of 2016 FDA granted Priority Review to the PKC412 (midostaurin) new drug application (NDA) for the treatment of acute myeloid leukemia (AML) in newly-diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, as well as for the treatment of advanced systemic mastocytosis (SM).
Originator
Sources: https://www.google.com/patents/US5093330
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/2714889
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034796 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12124173 |
528.0 nM [IC50] | ||
Target ID: ETV6-NTRK3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23131561 |
|||
Target ID: P04409 Gene ID: 282001.0 Gene Symbol: PRKCA Target Organism: Bos taurus (Bovine) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10454207 |
27.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | RYDAPT Approved UseRYDAPT is a kinase inhibitor indicated for the treatment of adult patients with:
Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation Launch Date1.49333764E12 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Analogs of staurosporine: potential anticancer drugs? | 1998 Nov |
|
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. | 2005 Dec 15 |
|
Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells. | 2009 Sep |
|
Effects of the protein kinase inhibitor PKC412 on gene expression and link to physiological effects in zebrafish Danio rerio eleuthero-embryos. | 2011 Jan |
|
Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia. | 2011 Oct 27 |
|
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. | 2011 Oct 27 |
|
Comprehensive analysis of kinase inhibitor selectivity. | 2011 Oct 30 |
|
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. | 2011 Oct 30 |
|
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | 2013 Apr 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22627678
50 mg twice daily for 14 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23131561
100 nM PKC412 treatment for 24 h induced the activation of caspase-3 and subsequently inactive the activity of PARP. Moreover, PKC412 treatment showed the inhibition of survivin, XIAP and Bcl-2 expression. The PKC412-induced apoptosis is further supported by the morphology findings that PKC412 treatment show the DNA damage and appearance of apoptotic bodies in IMS-M2 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:26:56 UTC 2022
by
admin
on
Fri Dec 16 17:26:56 UTC 2022
|
Record UNII |
ID912S5VON
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1742
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
||
|
EU-Orphan Drug |
EU/3/10/765
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
||
|
FDA ORPHAN DRUG |
306410
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
||
|
WHO-ATC |
L01XE39
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
||
|
NCI_THESAURUS |
C2089
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
||
|
NDF-RT |
N0000175605
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
||
|
FDA ORPHAN DRUG |
285909
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
656576
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
7677
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
CHEMBL608533
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
5231
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
1919083
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
C1872
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
9829523
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
ID912S5VON
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
QQ-30
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
120685-11-2
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
ID912S5VON
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
DB06595
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
C411007
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
Midostaurin
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
63452
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
SUB21040
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
M7534
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | Merck Index | ||
|
DTXSID40923522
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY | |||
|
Midostaurin
Created by
admin on Fri Dec 16 17:26:56 UTC 2022 , Edited by admin on Fri Dec 16 17:26:56 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE LESS ACTIVE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |